The effects of insulin Degludec on glucose fluctuation in patients with type 2 diabetes

The effects of insulin Degludec on glucose fluctuation in patients with type 2 diabetes - The effects of insulin Degludec on glucose fluctuation in patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012199

Enrollment

Registered

2013-11-01

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Insulin Glargine is replaced to insulin Degludec. CGM is performed before and immediately after replacement for 6 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)HbA1c value 6.5%-12%, type 2 diabetic patients 2)Patients medicated with insulin Glargine for more than 3 month

Exclusion criteria

Exclusion criteria: 1)Patients with hypersensitivity to Degludec 2)Patients with severe renal or liver failure 3)Patients with proliferative diabetic retinopathy (except for stable condition by photocoagulation) 4)Patients who are pregnant or in lactation period 5)Patients who achieve good plasma glucose levels by treatment with insulin Glargine 6)Juged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
Daily glucose fluctuation (MAGE,SD), incidence of hypoglycemia, change of QOL	—

Countries

Japan

Contacts

Public ContactYoshiro Kato

Aichi Medical University Division of Diabetes, Department of Internal Medicine, Diabetes Center

ykato4@aichi-med-u.ac.jp0561-63-1683

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026